Quiflapon sodium
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H326735

CAS#: 147030-01-1 (sodium)

Description: Quiflapon, also known as MK 0591, is a potent and selective 5-Lipoxygenase-activating protein (FLAP) inhibitor. MK-0591 is also a potent inhibitor of leukotriene (LT) biosynthesis in intact human and elicited rat polymorphonuclear leukocytes (PMNLs) (IC50 values 3.1 and 6.1 nM, respectively) and in human, squirrel monkey, and rat whole blood (IC50 values 510, 69, and 9 nM, respectively). MK-0591 has a high affinity for 5-lipoxygenase activating protein (FLAP) as evidenced by an IC50 value of 1.6 nM in a FLAP binding assay.

Chemical Structure

img
Quiflapon sodium
CAS# 147030-01-1 (sodium)
Instruction

Theoretical Analysis

Hodoodo Cat#: H326735
Name: Quiflapon sodium
CAS#: 147030-01-1 (sodium)
Chemical Formula: C34H34ClN2NaO3S
Exact Mass: 608.19
Molecular Weight: 609.157
Elemental Analysis: C, 67.04; H, 5.63; Cl, 5.82; N, 4.60; Na, 3.77; O, 7.88; S, 5.26

Price and Availability

Size Price Availability Quantity
10mg USD 390 2 Weeks
Bulk inquiry

Related CAS #: 136668-42-3 (free base)   147030-01-1 (sodium)    

Synonym: MK 0591; MK-0591; MK0591; L 686708; L-686708; L686708; L-686,708; L 686,708; L686,708; MK 591; MK591; MK-591; Quiflapon; Quiflapon sodium;

IUPAC/Chemical Name: sodium 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl)-2,2-dimethylpropanoate

InChi Key: YPURUCMVRRNPHJ-UHFFFAOYSA-M

InChi Code: InChI=1S/C34H35ClN2O3S.Na/c1-33(2,3)41-31-27-18-26(40-21-25-15-12-23-8-6-7-9-28(23)36-25)16-17-29(27)37(20-22-10-13-24(35)14-11-22)30(31)19-34(4,5)32(38)39;/h6-18H,19-21H2,1-5H3,(H,38,39);/q;+1/p-1

SMILES Code: O=C(C(C)(CC(N1CC2=CC=C(C=C2)Cl)=C(C3=C1C=CC(OCC4=NC5=CC=CC=C5C=C4)=C3)SC(C)(C)C)C)O[Na]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 609.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Park MS, Sohn MH, Kim KE, Park MS, Namgung R, Lee C. 5-Lipoxygenase-activating protein (FLAP) inhibitor MK-0591 prevents aberrant alveolarization in newborn mice exposed to 85% oxygen in a dose- and time-dependent manner. Lung. 2011 Feb;189(1):43-50. doi: 10.1007/s00408-010-9264-1. Epub 2010 Nov 5. PubMed PMID: 21052705.

2: Khougaz K, Clas SD. Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone) polymers. J Pharm Sci. 2000 Oct;89(10):1325-34. PubMed PMID: 10980507.

3: Depré M, Van Hecken A, Verbesselt R, De Lepeleire I, Schwartz J, Porras A, Larson P, Lin C, De Schepper PJ. Pharmacokinetic and pharmacodynamic interaction

between the lipoxygenase inhibitor MK-0591 and the cyclooxygenase inhibitor ibuprofen in man. Int J Clin Pharmacol Res. 1998;18(2):53-61. PubMed PMID: 9675622.

4: Uematsu T, Kanamaru M, Kosuge K, Hara K, Uchiyama N, Takenaga N, Tanaka W, Friedman BS, Nakashima M. Pharmacokinetic and pharmacodynamic analysis of a novel leukotriene biosynthesis inhibitor, MK-0591, in healthy volunteers. Br J Clin Pharmacol. 1995 Jul;40(1):59-66. PubMed PMID: 8527269; PubMed Central PMCID: PMC1365028.

5: Hillingsø J, Kjeldsen J, Laursen LS, Lauritsen K, von Spreckelsen S, Depré M,

Friedman BS, Malmström K, Shingo S, Bukhave K, et al. Blockade of leukotriene production by a single oral dose of MK-0591 in active ulcerative colitis. Clin Pharmacol Ther. 1995 Mar;57(3):335-41. PubMed PMID: 7697951.

6: Becker AB, Black C, Lilley MK, Bajwa K, Ford-Hutchinson AW, Simons FE, Tagari

P. Antiasthmatic effects of a leukotriene biosynthesis inhibitor (MK-0591) in allergic dogs. J Appl Physiol (1985). 1995 Feb;78(2):615-22. PubMed PMID: 7759431.

7: Diamant Z, Timmers MC, van der Veen H, Friedman BS, De Smet M, Depré M, Hilliard D, Bel EH, Sterk PJ. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol. 1995 Jan;95(1 Pt 1):42-51. PubMed PMID: 7822663.

8: Depré M, Friedman B, Van Hecken A, de Lepeleire I, Tanaka W, Dallob A, Shingo

S, Porras A, Lin C, de Schepper PJ. Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitor. Clin Pharmacol Ther. 1994 Jul;56(1):22-30. PubMed PMID: 8033491.

9: Stevens WH, Lane CG, Woolley MJ, Ellis R, Tagari P, Black C, Ford-Hutchinson A, O'Byrne PM. Effect of FLAP antagonist MK-0591 on leukotriene production and ozone-induced airway responses in dogs. J Appl Physiol (1985). 1994 Apr;76(4):1583-8. PubMed PMID: 8045835.

10: Tagari P, Becker A, Brideau C, Frenette R, Sadl V, Thomas E, Vickers P, Ford-Hutchinson A. Leukotriene generation and metabolism in dogs: inhibition of biosynthesis by MK-0591. J Pharmacol Exp Ther. 1993 Apr;265(1):416-25. PubMed PMID: 8386242.

11: Prasit P, Belley M, Blouin M, Brideau C, Chan C, Charleson S, Evans JF, Frenette R, Gauthier JY, Guay J, et al. A new class of leukotriene biosynthesis inhibitor: the development of MK-0591. J Lipid Mediat. 1993 Mar-Apr;6(1-3):239-44. PubMed PMID: 8357985.

12: Ménard L, Laviolette M, Borgeat P. Studies of the inhibitory activity of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol- 2-yl]-2,2-dimethyl propanoic acid) on arachidonic acid metabolism in human phagocytes. Can J Physiol Pharmacol. 1992 Jun;70(6):808-13. PubMed PMID: 1423024.

13: Brideau C, Chan C, Charleson S, Denis D, Evans JF, Ford-Hutchinson AW, Fortin R, Gillard JW, Guay J, Guévremont D, et al. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol. 1992 Jun;70(6):799-807. PubMed PMID: 1330258.